The UK-based maker of clinical genomics interpretation software is moving into the US and China after carefully researching the differences from European markets.
The Shenzhen-based company offers personal genomics services in China that are similar to those provided by 23andMe, Ancestry, and Helix in the US.
The change will be felt most immediately in Europe, where the Dutch molecular diagnostics company recently secured a CE-IVD mark for its MammaPrint BluePrint kit.
Centogene opened a Boston office in December and plans to open a lab there in a few months as it awaits an FDA decision on its clinical tool.
The Singapore-based firm has established a US subsidiary and named distributors to sell its products across Europe, the Middle East, and Asia.
LifeOmic, founded less than a year ago, expects omic data sets to become as clinically relevant as diagnostic medical imaging.
The La Jolla, California-based firm is moving beyond its US home market into other regions that promise growth for synthetic genomics providers.
The new division will enable BGI to expand partnerships with universities, companies, and health and agriculture-related organizations, among other things.
The company will focus on gaining customers for its custom and pre-defined hybrid capture kits first in Southern California, and then across the US.
Reuters reports that UK researchers are using gene-editing tools to develop flu-resistant chickens.
Nature calls for genomics to become part of the World Health Organization's cholera surveillance approach.
Vox explores a proposal to institute a lottery system to award grant funds.
In Genome Biology this week: gut microbiome study of individuals from Tanzania and Botswana, sixth version of the Network of Cancer Genes database, and more.